Cargando…

The Current State of Pharma and the FDA: Approval of a Dementia Drug as a Case in Point

Detalles Bibliográficos
Autor principal:	Eiser, Arnold R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Inc. 2021
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8674975/ https://www.ncbi.nlm.nih.gov/pubmed/34256026 http://dx.doi.org/10.1016/j.amjmed.2021.06.014

Ejemplares similares

Talking points for physicians, patients and caregivers considering Aduhelm® infusion and the accelerated pathway for its approval by the FDA
por: Gandy, Sam, et al.
Publicado: (2021)

Can an FDA-Approved Alzheimer’s Drug Be Repurposed for Alleviating Neuronal Symptoms of Zika Virus?
por: Sirohi, Devika, et al.
Publicado: (2017)

Monkeypox, smallpox, FDA, and accelerated approval of vaccines – A regulatory perspective
por: Sun, Wellington
Publicado: (2023)

Prescription Drugs Marketed in the United States Should Be Approved by the FDA
por: Shepherd, Marvin
Publicado: (2003)

Drugs, Devices, and the FDA: Part 2: An Overview of Approval Processes: FDA Approval of Medical Devices
por: Van Norman, Gail A.
Publicado: (2016)

Alchemical analysis of FDA approved drugs
por: Orsi, Markus, et al.
Publicado: (2023)

FDA Acceptance of Surrogate End Points for Cancer Drug Approval: 1992-2019
por: Chen, Emerson Y., et al.
Publicado: (2020)

The current landscape of the FDA approved companion diagnostics
por: Jørgensen, Jan Trøst
Publicado: (2021)

FDA approved vaccines for monkeypox: Current eminence
por: Chopra, Hitesh, et al.
Publicado: (2022)

Concerning FDA approval of trilaciclib (Cosela) in extensive-stage small-cell lung cancer
por: Powell, Kerrington, et al.
Publicado: (2021)

Food as pharma: marketing nutraceuticals to India’s rural poor
por: Street, Alice
Publicado: (2015)

FDA approved drugs as potential Ebola treatments
por: Ekins, Sean, et al.
Publicado: (2015)

FDA approved antibacterial drugs: 2018-2019
por: Andrei, Stefan, et al.
Publicado: (2019)

A systematic analysis of FDA-approved anticancer drugs
por: Sun, Jingchun, et al.
Publicado: (2017)

Big Pharma, Big Bucks, and a Big Pile o' Pigs
Publicado: (2001)

Quantitative analysis on the characteristics of targets with FDA approved drugs
por: Sakharkar, Meena K., et al.
Publicado: (2007)

The FDA guidance for industry on PROs: the point of view of a pharmaceutical company
por: Arpinelli, Fabio, et al.
Publicado: (2006)

Advancing therapeutics for recurrent clostridioides difficile infections: an overview of vowst’s FDA approval and implications
por: Jain, Nityanand, et al.
Publicado: (2023)

Tearing down the walls: FDA approves next generation sequencing (NGS) assays for actionable cancer genomic aberrations
por: Allegretti, Matteo, et al.
Publicado: (2018)

Repurposing FDA-approved drugs for anti-aging therapies
por: Snell, Terry W., et al.
Publicado: (2016)

New FDA approved antibacterial drugs: 2015-2017
por: Andrei, Stefan, et al.
Publicado: (2018)

Novel targeted drugs approved by the NMPA and FDA in 2019
por: Wang, Wenjing, et al.
Publicado: (2020)

Current FDA-Approved Therapies for High-Grade Malignant Gliomas
por: Fisher, Jacob P., et al.
Publicado: (2021)

Zika antiviral chemotherapy: identification of drugs and promising starting points for drug discovery from an FDA-approved library
por: Pascoalino, Bruno S., et al.
Publicado: (2016)

Pharmacogenetic Labeling of FDA-Approved Drugs: A Regulatory Retrospective
por: Drozda, Katarzyna, et al.
Publicado: (2018)

FDA Approvals of Biologics in 2022
por: Martins, Alexander C., et al.
Publicado: (2023)

A pragmatic regulatory approach for complex generics through the U.S. FDA 505(j) or 505(b)(2) approval pathways
por: Klein, Kevin, et al.
Publicado: (2021)

An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy
por: Tong, Juliana T. W., et al.
Publicado: (2021)

The approval and withdrawal of melphalan flufenamide (melflufen): Implications for the state of the FDA.
por: Olivier, Timothée, et al.
Publicado: (2022)

Drugs, Devices, and the FDA: Part 1: An Overview of Approval Processes for Drugs
por: Van Norman, Gail A.
Publicado: (2016)

FDA-Approved Drugs for Hematological Malignancies—The Last Decade Review
por: Sochacka-Ćwikła, Aleksandra, et al.
Publicado: (2021)

Bedaquiline: First FDA-approved tuberculosis drug in 40 years
por: Mahajan, Rajiv
Publicado: (2013)

Possible FDA-approved drugs to treat Ebola virus infection
por: Yuan, Shu
Publicado: (2015)

Repurposing of FDA-approved drugs against cancer – focus on metastasis
por: Ozsvári, Béla, et al.
Publicado: (2016)

Identification of FDA-approved drugs targeting the Farnesoid X Receptor
por: van de Wiel, Sandra M. W., et al.
Publicado: (2019)

Water Networks in Complexes between Proteins and FDA-Approved Drugs
por: Samways, Marley L., et al.
Publicado: (2022)

Ebanga™: The most recent FDA-approved drug for treating Ebola
por: Taki, Elahe, et al.
Publicado: (2023)

FDA-Approved Fluorinated Heterocyclic Drugs from 2016 to 2022
por: Rizzo, Carla, et al.
Publicado: (2023)

Chemistry and Pharmacology of Fluorinated Drugs Approved by the FDA (2016–2022)
por: Shabir, Ghulam, et al.
Publicado: (2023)

Synthesis and clinical application of new drugs approved by FDA in 2022
por: Zhang, Jing-Yi, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_59id37jps2mo0bso9b4efi5hpl